These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17204356)

  • 21. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
    Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs.
    Lu Z
    Contemp Clin Trials; 2010 Jan; 31(1):108-18. PubMed ID: 19900576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
    Kingston R
    Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
    [No Abstract]   [Full Text] [Related]  

  • 24. Early identification systems for emerging foodborne hazards.
    Marvin HJ; Kleter GA; Prandini A; Dekkers S; Bolton DJ
    Food Chem Toxicol; 2009 May; 47(5):915-26. PubMed ID: 18272277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 28. The state of adverse event reporting and signal generation of dietary supplements in Korea.
    Park KS; Kwon O
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):74-7. PubMed ID: 20074608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An appraisal of spontaneous adverse event monitoring.
    Fletcher AP
    Adverse Drug React Toxicol Rev; 1992; 11(4):213-27. PubMed ID: 1489882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk management and post-marketing surveillance of CNS drugs.
    Henningfield JE; Schuster CR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
    Lilienfeld DE
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
    Kunac DL; Harrison-Woolrych M; Tatley MV
    N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European biologicals registers: methodology, selected results and perspectives.
    Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
    Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Causality methods in cosmetovigilance: comparison of Colipa and PLM versus global introspection.
    Zweers PG; Gilmour NJ; Hepburn PA; Gerritsen RF; van Puijenbroek EP
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):409-17. PubMed ID: 22609380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.